Technology Insight: applications of emerging immunotherapeutic strategies for Epstein–Barr virus-associated malignancies

@article{Khanna2005TechnologyIA,
  title={Technology Insight: applications of emerging immunotherapeutic strategies for Epstein–Barr virus-associated malignancies},
  author={Rajiv Khanna and Denis J. Moss and Maher K. Gandhi},
  journal={Nature Clinical Practice Oncology},
  year={2005},
  volume={2},
  pages={138-149}
}
The Epstein–Barr virus (EBV) is uniquely associated with a broad range of human malignancies. In spite of their diverse cellular origin, most of these malignancies share common features, including the expression of either some or all of the EBV latent proteins, which can be potentially exploited for immune-based therapies. Here we discuss new and emerging strategies to manipulate the immune response to specifically boost T-cell immunity towards viral proteins that are expressed in EBV… Expand
Epstein-Barr virus: novel patented therapeutics.
TLDR
Many promising therapeutic opportunities are identified, among these, vaccination protocols and adoptive cellular therapies are the most advanced and reached Phase I/II clinical trials. Expand
Epstein–Barr virus: novel patented therapeutics
  • P. De Paoli
  • Medicine
  • Expert opinion on therapeutic patents
  • 2010
TLDR
Many promising therapeutic opportunities are identified, among these, vaccination protocols and adoptive cellular therapies are the most advanced and reached Phase I/II clinical trials. Expand
Immunotherapy for Epstein-Barr Virus-Related Lymphomas
TLDR
The current immunotherapies and future studies aimed at targeting EBV antigen expression in these tumors are reviewed. Expand
Current understanding of the role of Epstein–Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas
TLDR
T cells specific for the weakly immunogenic latent membrane protein 2 have been expanded ex vivo and have promoted tumor regression in a subset of patients and another potential therapeutic strategy could be to try to induce lytic EBV infection in the tumor cells. Expand
Generation of cytotoxic T lymphocytes for immunotherapy of EBV-associated malignancies.
TLDR
Cytotoxic T cell (CTL)-based immunotherapy offers an alternative approach that is designed to specifically target protein antigens expressed in malignant cells and is thus likely to limit any adverse side-effects. Expand
Epstein–Barr Virus‐Related Post‐Transplant Lymphoproliferative Disorders: Pathogenetic Insights for Targeted Therapy
  • J. Nourse, K. Jones, M. K. Gandhi
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2011
TLDR
The interplay between aspects of the EBV life cycle and latency with nonviral factors resulting in the wide spectrum of histology and clinical presentations encountered in PTLD is discussed. Expand
Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.
TLDR
This experiment of nature provides a system to advance understanding of immunological homeostasis in humans, illustrating how data obtained from the study of EBV have wider significance to the immunological community. Expand
T-cell therapy in the treatment of post-transplant lymphoproliferative disease
TLDR
This Review describes current approaches of T-cell-based therapies to treat PTLD, and describes strategies that improve the feasibility of such treatment. Expand
Viruses and lymphoma
TLDR
Research is likely to uncover new lymphoma associations between both known and as yet unidentified viruses, may provide cellular and pharmacological targeted antiviral therapy strategies for the treatment of malignant lymphoma, and ultimately may generate the most promising avenue for lymphoma prevention. Expand
Therapeutic implications of Epstein–Barr virus infection for the treatment of nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) is highly endemic in certain regions including the People’s Republic of China and Southeast Asia. Its etiology is unique and multifactorial, involving geneticExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Immune regulation in Epstein-Barr virus-associated diseases.
TLDR
The role of the immune system in controlling EBV infection in healthy individuals and in individuals with EBV-associated diseases is discussed, and the likelihood of producing a vaccine capable of controlling the acute viral infection and EBv-associated malignancies is discussed. Expand
The LMP2A signalosome--a therapeutic target for Epstein-Barr virus latency and associated disease.
TLDR
A more complete understanding of the role of LMP2A in EBV latency and tumorigenesis is provided and may allow for the identification of novel therapeutics for the treatment or eradication of EBV latent infections and associated proliferative disorders. Expand
Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease
TLDR
The performance and fate of these human tumor antigen–specific T cells in vivo suggests that they might be of value for the treatment of EBV+ Hodgkin lymphoma. Expand
Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
TLDR
Preclinical studies using a recombinant poxvirus vaccine that encodes a polyepitope protein comprising 6 HLA A2-restricted epitopes derived from LMP1 provide an important platform for the development of an LMP-based polyepITope vaccine as an immunotherapeutic tool for the treatment of EBV-associated HD and NPC. Expand
Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases.
TLDR
An overview of virus and the host immune system interactions that regulate the life-long host-virus relationship in healthy virus carriers and EBV-associated diseases is presented. Expand
Adoptive immunotherapy with allogeneic Epstein–Barr virus (EBV)‐specific cytotoxic T‐lymphocytes for recurrent, EBV‐positive Hodgkin disease
It has been shown that adoptive immunotherapy with Epstein–Barr virus (EBV)‐specific cytotoxic T‐lymphocytes (CTL) is effective for the treatment of EBV‐induced lymphoproliferative disease in stemExpand
Establishment and Characterization of a Bank of Cytotoxic T Lymphocytes for Immunotherapy of Epstein-Barr Virus-Associated Diseases
TLDR
The establishment of a cryopreserved repository of allogeneic virus-specific CTL lines, to the authors' knowledge the first of its kind in the world, is described, superseding the time-consuming, expensive practice of generating autologous CTLs from each patient requiring treatment. Expand
B cells under influence: transformation of B cells by Epstein–Barr virus
  • R. Küppers
  • Biology, Medicine
  • Nature Reviews Immunology
  • 2003
TLDR
Intriguingly, the three main types of EBV-associated B-cell lymphoma — that is, Burkitt lymphoma, Hodgkin lymphoma and post-transplant lymphomas — seem to derive from germinal-centre B cells or atypical survivors of the germinalscentre reaction in most, if not all, cases, indicating that EBV -infected germinAL-cent centre B cells are at particular risk for malignant transformation. Expand
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.
TLDR
It is demonstrated that EBV-specific cytotoxic T-cell lines can readily be generated from individuals with NPC, notwithstanding the patients' prior exposure to chemotherapy/radiation, and can be associated with significant antitumor activity. Expand
Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.
TLDR
Preliminary data obtained in this patient indicate that EBV-specific CTLs are safe, may exert specific killing of NPC tumor cells in vitro, and induce antitumor effect in vivo. Expand
...
1
2
3
4
5
...